Medicenna's MDNA11 shows 30-40% response rates in checkpoint-resistant cancers, with Phase 1/2 data expected in Q4 2026.

J&J's nipocalimab showed significant functional improvements in early-stage myasthenia gravis patients, with benefits sustained through infections.

FDA approves risankizumab for pediatric psoriasis and psoriatic arthritis in children six years and older, expanding treatment options for...

A cluster-RCT across 16 Kenya primary care clinics found ChatGPT-4o-assisted decision support improved documentation but missed on patient outcomes...

Silo Pharma's SPC-15 PTSD treatment passes nine months of stability testing, clearing a key CMC milestone toward IND submission...

Seres presents SER-155 data for checkpoint inhibitor enterocolitis, targeting a steroid-sparing approach to oncology-related toxicity management.

An MHRA inspection at King's College Hospital flagged department-wide GCP failures in the exenatide Phase 3 Parkinson's trial, triggering...

ProQR's AX-0810 Phase 1 study demonstrates target engagement through an 8-fold increase in serum bile acids, validating the Axiomer...

Innovative Molecules launches Phase 2a Trial of Adibelivir for genital herpes, testing a helicase-primase inhibitor against acyclovir-resistant strains.

FDA backs Entera Bio's Phase 3 plan for oral EB613 osteoporosis drug, targeting injection-free anabolic therapy for postmenopausal women.